• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Chromosome 17p Deletion

Chromosome 17p Deletion - 12 Studies Found

Completed : A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
:
  • Chronic Lymphocytic Leukemia With 17p Deletion
  • Small Lymphocyti
    : 2012-12-03
    : Drug: Ibrutinib All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.
Terminated : Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
: B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
: 2014-01-22
:
  • Drug: Idelalisib 150 mg tablet

Active, not recruiting : A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion
:
  • Chronic Lymphocytic Leukemia
  • 17 p Deletion
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

: 2014-11-19
:
  • Drug: acalabrutinib Patients u

Completed : Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
:
  • CLL
  • SLL

: 2011-10-18
:
  • Drug: Ofatumumab 1000 mg IV

Completed : Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine
: Chronic Lymphocytic Leukemia
: 2011-06-28
: Drug: Alemtuzumab Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
Completed : A Study Evaluating Venetoclax in Subjects With Chronic Lymphocytic Leukemia Whose Cancer Has Come Back or Who Had No Response to Previous Cancer Treatments Including Subjects Missing Part of Their Chromosome 17, or TP53 Gene Mutation; or Who Received Prior Treatment With a B-Cell Receptor Inhibitor
: Chronic Lymphocytic Leukemia (CLL)
: 2016-11-30
: Drug: Venetoclax Tablet Other Name: ABT-199
Completed : Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia
: Chronic Lymphocytic Leukemia
: 2013-12-03
: Drug: Ruxolitinib 20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progres
Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.